Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
14.29 (USD) • At close February 4, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2001 | |
|---|---|---|---|---|---|---|
| Revenue
| 251.455 | 477.706 | 313.837 | 76.657 | 54.184 | 98.285 |
| Cost of Revenue
| 54.005 | 204.216 | 129.69 | 15.611 | 0 | 0 |
| Gross Profit
| 197.45 | 273.49 | 184.147 | 61.046 | 54.184 | 98.285 |
| Gross Profit Ratio
| 0.785 | 0.573 | 0.587 | 0.796 | 1 | 1 |
| Reseach & Development Expenses
| 580.621 | 1,052.643 | 1,149.662 | 159.767 | 96.299 | 100.476 |
| General & Administrative Expenses
| 385.025 | 1,429.799 | 862.952 | 38.306 | 29.483 | 77.393 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 385.025 | 1,429.799 | 862.952 | 38.306 | 29.483 | 77.393 |
| Other Expenses
| 96.21 | 7.634 | -1.733 | 16.125 | 1.574 | 0 |
| Operating Expenses
| 1,061.856 | 2,482.442 | 2,012.614 | 198.073 | 125.782 | 177.869 |
| Operating Income
| -864.406 | -2,208.952 | -1,828.467 | -137.027 | -71.598 | -234.508 |
| Operating Income Ratio
| -3.438 | -4.624 | -5.826 | -1.788 | -1.321 | -2.386 |
| Total Other Income Expenses Net
| -28.534 | 87.553 | -9.655 | 12.193 | -48.237 | 0 |
| Income Before Tax
| -892.94 | -2,121.399 | -1,838.122 | -124.834 | -119.835 | 0 |
| Income Before Tax Ratio
| -3.551 | -4.441 | -5.857 | -1.628 | -2.212 | 0 |
| Income Tax Expense
| -0.071 | -15.027 | -1.48 | 1.889 | 0.022 | 0 |
| Net Income
| -892.869 | -2,104.929 | -1,830.047 | -126.609 | -119.327 | 0 |
| Net Income Ratio
| -3.551 | -4.406 | -5.831 | -1.652 | -2.202 | 0 |
| EPS
| -18.37 | -50.15 | -53.83 | -0.085 | -0.08 | 0 |
| EPS Diluted
| -18.37 | -50.12 | -53.81 | -0.085 | -0.08 | 0 |
| EBITDA
| -821.293 | -2,059.659 | -1,806.673 | -108.585 | -106.659 | -219.712 |
| EBITDA Ratio
| -3.266 | -4.564 | -5.983 | -1.403 | -1.496 | -2.235 |